Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Trimmed by Bain Capital Life Sciences Investors LLC

Bain Capital Life Sciences Investors LLC decreased its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 10.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,689,707 shares of the company's stock after selling 323,716 shares during the period. Dianthus Therapeutics comprises about 6.9% of Bain Capital Life Sciences Investors LLC's investment portfolio, making the stock its 5th biggest position. Bain Capital Life Sciences Investors LLC owned 9.09% of Dianthus Therapeutics worth $58,636,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. R Squared Ltd purchased a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at $26,000. KLP Kapitalforvaltning AS purchased a new stake in Dianthus Therapeutics during the fourth quarter valued at about $33,000. KBC Group NV bought a new position in shares of Dianthus Therapeutics during the fourth quarter valued at about $35,000. AlphaQuest LLC lifted its stake in shares of Dianthus Therapeutics by 273.1% in the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock valued at $91,000 after acquiring an additional 3,072 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new stake in Dianthus Therapeutics during the 4th quarter valued at about $201,000. Hedge funds and other institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Trading Up 2.1 %

NASDAQ DNTH traded up $0.44 during trading on Friday, hitting $21.67. The company had a trading volume of 198,482 shares, compared to its average volume of 261,961. The company's fifty day moving average is $19.97 and its 200-day moving average is $22.91. The company has a market cap of $696.17 million, a price-to-earnings ratio of -8.67 and a beta of 1.62. Dianthus Therapeutics, Inc. has a one year low of $13.37 and a one year high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. As a group, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on DNTH. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush reiterated an "outperform" rating and set a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Guggenheim reissued a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $54.33.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.